Robin Sherrington

Robin Sherrington serves as the Executive Vice President at Xenon Pharmaceuticals Inc., a company focused on developing innovative therapies in the healthcare sector. His recent insider trading activity, captured in SEC Form 4 filings, reveals a pattern of sale transactions between January 2, 2024, and March 12, 2024, with reported amounts ranging from $73,000 to $2.9 million. Notably, the largest disclosed move was a grant/exercise valued at approximately $2.88 million on March 12, 2024, highlighting his significant role within the company.